FDA Conditionally Approves New Drug for Screwworm Infestation in Dogs
In a significant move for animal health, the U.S. Food and Drug Administration has granted conditional approval for Credelio Quattro-CA1 chewable tablets. This new medication, containing lotilaner, moxidectin, praziquantel, and pyrantel, is specifically formulated to combat infestations by New World screwworm (NWS) larvae, also known as myiasis, in canines. The treatment is deemed suitable for dogs and puppies aged eight weeks or older, provided they weigh a minimum of 3.3 pounds.
This conditional approval is a testament to the drug's assessed safety and its promising likelihood of effectiveness for its designated purpose. Elanco US Inc., the pharmaceutical sponsor, is now tasked with submitting further effectiveness data over the next five years to secure full approval. The product's expedited review was facilitated by its focus on a serious animal disease, its capacity to fulfill an unmet need in veterinary care, and the complexity involved in conducting exhaustive effectiveness studies. Furthermore, it received priority zoonotic animal drug designation from the FDA.
While the majority of dogs across the United States face a relatively low risk from New World screwworm, the potential for exposure escalates in regions bordering Mexico and for dogs that have traveled to affected territories. Credelio Quattro-CA1 will be exclusively available through veterinary prescription, ensuring controlled distribution and proper administration for the benefit of canine patients.
This advancement represents a proactive step in safeguarding canine well-being, particularly in vulnerable populations. The commitment to developing and approving such specialized treatments underscores the ongoing dedication within the veterinary and regulatory communities to address critical animal health challenges, fostering a future where companion animals can lead healthier, more protected lives.